SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
“New Drug” Designations for New Therapeutic Entities: New Active Substance, New Chemical Entity, New Biological Entity, New Molecular Entity
7 references·0 citing·21 second hop
“New Drug” Designations for New Therapeutic Entities: New Active Substance, New Chemical Entity, New Biological Entity, New Molecular Entity (2014)“New Drug” Designations for New Therapeut…Overlapping Intellectual Property Rights (2023)Overlapping Intellectual Prop…2013 FDA drug approvals (2014)2013 FDA drug approvalsExpediting Drug Development — The FDA's New “Breakthrough Therapy” Designation (2013)Expediting Drug Development —…Urban legends of chemistry (2010)Urban legends of chemistryThe strategy of enantiomer patents of drugs (2010)The strategy of enantiomer pa…Follow-on biologics: data exclusivity and the balance between innovation and competition (2008)Follow-on biologics: data exc…FDA'S policy statement for the development of new stereoisomeric drugs (1992)FDA'S policy statement for th…Intellectual property and chirality of drugs (1999)Secondary Patenting Of Branded Pharmaceuticals: A Case Study Of How Patents On Two HIV Drugs Could Be Extended For Decades (2012)The predicated demise of racemic new molecular entities is an exaggeration (2012)Chiral Switch: Between Therapeutical Benefit and Marketing Strategy (2022)Improvised News: A Sociological Study of Rumor. (1969)Grooming, Gossip, and the Evolution of Language (1998)Grooming, gossip, and the evolution of language (1998)Industrial Market Structure and Economic Performance. (1971)Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) (2000)The price of innovation: new estimates of drug development costs (2003)Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine (2013)Determinants of Market Exclusivity for Prescription Drugs in the United States (2017)The Impact of the Entry of Biosimilars: Evidence from Europe (2018)National trends in prescription drug expenditures and projections for 2014 (2014)New FDA Breakthrough-Drug Category — Implications for Patients (2014)Early market access of cancer drugs in the EU (2015)Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006–2022) (2025)Patent protection strategies (2010)Confidential Information as Property? (2013)Overlapping rights: the negative effects of trademarking creative works (2014)Using computer vision to measure design similarity: An application to design rights (2025)
this work references cited by second hop

References

  • 1992FDA'S policy statement for the development of new stereoisomeric drugs581 cited
  • 2013Expediting Drug Development — The FDA's New “Breakthrough Therapy” Designation139 cited
  • 20142013 FDA drug approvals97 cited
  • 2008Follow-on biologics: data exclusivity and the balance between innovation and competition89 cited
  • 2010The strategy of enantiomer patents of drugs61 cited
  • 2023Overlapping Intellectual Property Rights20 cited
  • 2010Urban legends of chemistry7 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work